NCX 1102

Drug Profile

NCX 1102

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NicOx
  • Class Antineoplastics; Chemopreventatives; Indenes
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Sep 2004 Preclinical trials in Cancer and Cancer (Prevention)/Chemoprevention in France (unspecified route)
  • 02 Sep 2004 A preclinical study has been added to the Cancer pharmacodynamics section ,
  • 01 Oct 2001 Preclinical development for Cancer and Cancer (Prevention)/Chemoprevention in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top